Benefit of Erlotinib in Patients with Non-Small-Cell Lung Cancer Is Related to Smoking Status, Gender, Skin Rash and Radiological Response but Not to Histology and Treatment Line

Publisher： Karger

E-ISSN： 1423-0232|78|3-4|249-258

ISSN： 0030-2414

Source： Oncology, Vol.78, Iss.3-4, 2010-06, pp. : 249-258

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prognosis in Patients with Non-Small Cell Lung Cancer Who Received Erlotinib Treatment and Subsequent Dose Reduction due to Skin Rash

By  

Oncology Research and Treatment, Vol. 35, Iss. 12, 2012-11 ,pp. : 747-752

Karger

Access to resources Recommend Favorite

Treating Non-Small-Cell Lung Cancer First Line with Erlotinib Monotherapy in Elderly Patients: Discussion of a Case Series

By  

Oncology Research and Treatment, Vol. 30, Iss. 10, 2007-09 ,pp. : 515-518

Karger

Access to resources Recommend Favorite

Antiangiogenic Agents Combined with Chemotherapy in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Overall and Histology Subgroup-Specific Meta-Analysis

By  

Oncology Research and Treatment, Vol. 37, Iss. 12, 2014-11 ,pp. : 710-718

Karger

Access to resources Recommend Favorite

The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients

By  

Respiration, Vol. 82, Iss. 4, 2011-01 ,pp. : 341-350

Karger

Access to resources Recommend Favorite

Erlotinib for Metastatic Non-Small-Cell Lung Cancer: First-, Second- or Third-Line Setting – Does It Matter ?

By  

Oncology, Vol. 76, Iss. 2, 2008-12 ,pp. : 85-90

Karger

Access to resources Recommend Favorite